| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD66c; CEACAM6; CEAL; NCA; Non specific cross reacting antigen; Normal cross reacting antigen;;CEACAM6 |
| WB Predicted band size | 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human CEACAM6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于CEACAM6抗体的代表性文献摘要(文献信息为虚拟示例，仅供格式参考)：
---
1. **标题**: CEACAM6 as a Therapeutic Target in Pancreatic Cancer
**作者**: Smith A, et al.
**期刊**: *Cancer Research* (2020)
**摘要**: 研究证实CEACAM6在胰腺癌中高表达，其抗体通过阻断肿瘤细胞间黏附和EGFR信号通路，显著抑制小鼠模型中肿瘤转移，提示其作为靶向治疗的潜力。
---
2. **标题**: Anti-CEACAM6 Antibody-Drug Conjugate in Breast Cancer
**作者**: Zhang L, et al.
**期刊**: *Clinical Cancer Research* (2018)
**摘要**: 开发了一种CEACAM6抗体-药物偶联物(ADC)，在体外和三阴性乳腺癌小鼠模型中显示出选择性杀伤肿瘤细胞的效果，且对正常组织毒性较低。
---
3. **标题**: CEACAM6 Promotes Chemoresistance via Antibody-Mediated Autophagy Inhibition
**作者**: Kim H, et al.
**期刊**: *Oncotarget* (2019)
**摘要**: 研究发现CEACAM6抗体可通过抑制肿瘤细胞自噬途径，逆转结直肠癌细胞对奥沙利铂的耐药性，为联合化疗提供新策略。
---
(注：以上文献为示例性内容，实际研究中请通过PubMed/Web of Science等平台检索真实文献)
CEACAM6 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the CEACAM family, which plays roles in intercellular adhesion, immune modulation, and tumor progression. It is overexpressed in various cancers, including pancreatic, colorectal, breast, and lung adenocarcinomas, where it promotes tumor cell survival, metastasis, and resistance to therapy by regulating signaling pathways like PI3K/AKT and integrin-mediated processes. CEACAM6 antibodies are immunodetection tools or therapeutic agents targeting this protein.
In research, CEACAM6 antibodies are widely used to study its biological functions, tumor microenvironments, and biomarker potential via techniques such as immunohistochemistry, flow cytometry, or Western blot. Therapeutically, anti-CEACAM6 antibodies are explored for targeted drug delivery (e.g., antibody-drug conjugates) or immune-based therapies, leveraging their specificity to inhibit CEACAM6-mediated oncogenic signaling or induce antibody-dependent cellular cytotoxicity (ADCC). Challenges include optimizing binding affinity, minimizing off-target effects, and addressing heterogeneity in CEACAM6 expression across tumors. Recent studies also highlight its role in immune evasion, making it a candidate for combination therapies with checkpoint inhibitors. Despite preclinical promise, clinical translation remains limited, necessitating further validation of safety and efficacy in human trials.
×
